As of 2025-03-19, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -4.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 926.66 mil USD. NRIX's TTM EBITDA according to its financial statements is -196.60 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 15.0x | 13.6x |
| Forward P/E multiples | 21.9x - 48.3x | 35.1x |
| Fair Price | (55.28) - (37.41) | (61.63) |
| Upside | -504.7% - -373.9% | -551.2% |
| Date | EV/EBITDA |
| 2025-03-18 | -4.71 |
| 2025-03-17 | -4.82 |
| 2025-03-14 | -4.69 |
| 2025-03-13 | -4.53 |
| 2025-03-12 | -5.05 |
| 2025-03-11 | -4.81 |
| 2025-03-10 | -4.69 |
| 2025-03-07 | -4.79 |
| 2025-03-06 | -4.86 |
| 2025-03-05 | -4.95 |
| 2025-03-04 | -4.95 |
| 2025-03-03 | -4.92 |
| 2025-02-28 | -5.40 |
| 2025-02-27 | -5.23 |
| 2025-02-26 | -6.03 |
| 2025-02-25 | -5.80 |
| 2025-02-24 | -5.95 |
| 2025-02-21 | -5.95 |
| 2025-02-20 | -6.02 |
| 2025-02-19 | -6.14 |
| 2025-02-18 | -5.90 |
| 2025-02-14 | -6.23 |
| 2025-02-13 | -6.22 |
| 2025-02-12 | -6.12 |
| 2025-02-11 | -6.05 |
| 2025-02-10 | -6.39 |
| 2025-02-07 | -6.73 |
| 2025-02-06 | -6.79 |
| 2025-02-05 | -6.85 |
| 2025-02-04 | -6.62 |
| 2025-02-03 | -6.76 |
| 2025-01-31 | -7.05 |
| 2025-01-30 | -7.17 |
| 2025-01-29 | -7.03 |
| 2025-01-28 | -6.99 |
| 2025-01-27 | -7.09 |
| 2025-01-24 | -7.13 |
| 2025-01-23 | -7.15 |
| 2025-01-22 | -7.04 |
| 2025-01-21 | -7.01 |
| 2025-01-17 | -6.83 |
| 2025-01-16 | -6.96 |
| 2025-01-15 | -7.22 |
| 2025-01-14 | -6.62 |
| 2025-01-13 | -6.78 |
| 2025-01-10 | -6.48 |
| 2025-01-08 | -6.97 |
| 2025-01-07 | -6.74 |
| 2025-01-06 | -6.86 |
| 2025-01-03 | -7.05 |